BR112022015626A2 - Composição e métodos de vacinas de mrna contra infecção de novo coronavírus - Google Patents

Composição e métodos de vacinas de mrna contra infecção de novo coronavírus

Info

Publication number
BR112022015626A2
BR112022015626A2 BR112022015626A BR112022015626A BR112022015626A2 BR 112022015626 A2 BR112022015626 A2 BR 112022015626A2 BR 112022015626 A BR112022015626 A BR 112022015626A BR 112022015626 A BR112022015626 A BR 112022015626A BR 112022015626 A2 BR112022015626 A2 BR 112022015626A2
Authority
BR
Brazil
Prior art keywords
methods
mrna
composition
mrna vaccines
vaccines against
Prior art date
Application number
BR112022015626A
Other languages
English (en)
Inventor
Tang Shenggao
Shen Dong
Lu Chun
He Ziyang
He Jiaxi
y lu Patrick
Original Assignee
Rnaimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rnaimmune Inc filed Critical Rnaimmune Inc
Publication of BR112022015626A2 publication Critical patent/BR112022015626A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

COMPOSIÇÃO E MÉTODOS DE VACINAS DE mRNA CONTRA INFECÇÃO DE NOVO CORONAVÍRUS. Composições e métodos são fornecidos para vacinas de mRNA potentes para prevenção e tratamento de novas infecções por Coronavírus de 2019 (2019-nCoV). As composições incluem uma composição farmacêutica contendo uma ou mais moléculas de mRNA que codificam epítopos de proteína spike, incluindo epítopos mutados ou coquetéis de mRNA que codificam genes virais críticos juntamente com carreadores de nanopartículas poliméricas farmaceuticamente aceitáveis e carreadores de nanopartículas lipossômicas. São fornecidos métodos e tratamento para estimular respostas imunes do sistema, incluindo injeções subcutâneas, intraperitoneais e intramusculares.
BR112022015626A 2020-02-07 2021-02-08 Composição e métodos de vacinas de mrna contra infecção de novo coronavírus BR112022015626A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062971834P 2020-02-07 2020-02-07
US202063058463P 2020-07-29 2020-07-29
US202063130581P 2020-12-24 2020-12-24
PCT/US2021/017149 WO2021159118A2 (en) 2020-02-07 2021-02-08 Composition and method of mrna vaccines against novel coronavirus infection

Publications (1)

Publication Number Publication Date
BR112022015626A2 true BR112022015626A2 (pt) 2022-10-11

Family

ID=77200778

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015626A BR112022015626A2 (pt) 2020-02-07 2021-02-08 Composição e métodos de vacinas de mrna contra infecção de novo coronavírus

Country Status (11)

Country Link
US (2) US20220040292A1 (pt)
EP (1) EP4100066A4 (pt)
JP (1) JP2023512833A (pt)
KR (1) KR20220143684A (pt)
CN (1) CN115297892A (pt)
AU (1) AU2021216443A1 (pt)
BR (1) BR112022015626A2 (pt)
CA (1) CA3167257A1 (pt)
IL (1) IL295360A (pt)
MX (1) MX2022009688A (pt)
WO (1) WO2021159118A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138897A1 (en) 2020-04-22 2023-03-01 BioNTech SE Coronavirus vaccine
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
CN113881806A (zh) * 2021-09-23 2022-01-04 华南理工大学 基于CRISPR/Cas12a技术检测新冠病毒和69/70突变株的方法及试剂盒
EP4183409A1 (en) 2021-11-17 2023-05-24 Charité - Universitätsmedizin Berlin Vaccine with improved immunogenicity against mutant coronaviruses
WO2023094713A2 (en) * 2021-11-29 2023-06-01 BioNTech SE Coronavirus vaccine
WO2023146230A1 (ko) 2022-01-27 2023-08-03 에스케이바이오사이언스 주식회사 단백질 발현을 위한 mrna와 이를 위한 주형
WO2023196759A2 (en) * 2022-04-03 2023-10-12 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
WO2024002985A1 (en) * 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
KR20240002207A (ko) * 2022-06-26 2024-01-04 비온테크 에스이 코로나바이러스 백신

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059127T2 (hu) * 2015-10-22 2022-10-28 Modernatx Inc Légúti vírusok elleni vakcinák
US11141476B2 (en) * 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
CN110520155A (zh) * 2017-02-28 2019-11-29 广州纳泰生物医药技术有限公司 预防和治疗寨卡病毒感染的rna药物制剂
US20230117167A1 (en) * 2020-01-28 2023-04-20 Codagenix Inc. DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Also Published As

Publication number Publication date
EP4100066A2 (en) 2022-12-14
EP4100066A4 (en) 2024-05-01
CN115297892A (zh) 2022-11-04
AU2021216443A1 (en) 2022-09-08
US20220040292A1 (en) 2022-02-10
KR20220143684A (ko) 2022-10-25
CA3167257A1 (en) 2021-08-12
WO2021159118A3 (en) 2021-10-28
JP2023512833A (ja) 2023-03-29
US20230108926A1 (en) 2023-04-06
WO2021159118A8 (en) 2022-09-22
WO2021159118A2 (en) 2021-08-12
IL295360A (en) 2022-10-01
MX2022009688A (es) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112022015626A2 (pt) Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
Wang et al. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
HRP20141125T1 (hr) Postupak sprjeäśavanja ili lijeäśenja infekcije bakterijom m. tuberculosis
SI2280721T1 (en) IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
RU2014134365A (ru) Вакцины против clostridium difficile, включающие рекомбинантные токсины
WO2022043551A3 (en) Multivalent nucleic acid based coronavirus vaccines
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
CL2020000295A1 (es) Métodos de terapia génica del factor viii (fviii)
BR112022014578A2 (pt) Composição e métodos de profiláticos e terapêuticos de rnai para o tratamento de infecção respiratória aguda grave causada pelo novo coronavírus 2019 (2019-ncov)
BR112023000220A2 (pt) Formulações de longa ação
BR112023021654A2 (pt) Vacina contra vírus
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
Yu et al. Effects of IBDV infection on expression of chTLRs in chicken bursa
BR112018072719A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos de indução de uma resposta imune contra o filovírus e o ebolavirus, de tratamento de um indivíduo que foi diagnosticado com ebolavirus e de prevenção da infecção por ebolavirus
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
Parhiz et al. mRNA-based therapeutics: looking beyond COVID-19 vaccines
US11419928B2 (en) Methods and compositions for treating cancer
AU2021100256A4 (en) Application of Mixture of Rg1 and Oil in Preparation of Rabbit Bordetella Vaccine Adjuvant

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]